Alto Neuroscience, Inc.
ANRO
$34.32
-$1.49-4.16%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -56.09% | -72.96% | -6.45% | 15.50% | -10.46% |
| Total Depreciation and Amortization | 8.88% | 7.60% | -7.65% | 34.43% | 49.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 64.51% | 8.19% | 26.06% | 30.39% | -11.82% |
| Change in Net Operating Assets | 181.24% | 5.71% | 2,021.21% | -53.45% | -9.44% |
| Cash from Operations | -43.41% | -63.63% | 11.56% | 15.42% | -17.83% |
| Capital Expenditure | -- | -2,216.67% | 100.00% | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -2,216.67% | 100.00% | 100.00% | 100.00% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 60,509.09% | 102,659.18% | 128.36% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -154.01% | -792.86% | -- | -- | 53.56% |
| Cash from Financing | -144.54% | 1,159.35% | 102,318.37% | -88.38% | 361.97% |
| Foreign Exchange rate Adjustments | 233.33% | 27.27% | -116.67% | 42.86% | 40.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -52.09% | 1,267.60% | 387.02% | 14.46% | -7.30% |